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Abstract
Introduction:  A great deal of data regarding the toxicology of mercury has been recently
reported. Although the most common human exposures to mercury are currently mercury vapour
from amalgam tooth fillings, methylmercury from seafood and ethylmercury as a preservative in
vaccines, in the past mercury compounds have been used in the treatment of syphilis.
Case presentation: Mercury intoxication was found in a 67 year-old Italian man affected by
neurological symptoms of apparently unknown origin. The patient developed syphilis forty years
ago and then underwent therapy with mercurials to treat his chronic bacterial infection. We
treated the patient with disodium edetate chelation therapy.
Six months after the beginning of the therapy, the patient's neurological symptoms began to
decrease, and were completely cured after two years of therapy.
Conclusion: This case supports the use of chelation therapy with disodium edetate to remove
damages caused by mercury intoxication.
Introduction
Between 1916 and 1955 important advances were made
in the treatment of syphilis. During the first years of this
period arsenicals, mercurials, malaria therapy and heat
therapy were used, then these treatments were progres-
sively replaced by the use of penicillin [1]. However, in
the years prior to 1916, the treatment of syphilis consisted
of the use of heavy metals, initially with mercurial and
later with arsenic and bismuth preparations. Patients
treated with heavy metals often developed neurological
symptoms which were then described as neurosyphilis
[2]. Although new medications supplanted mercury it was
still used sporadically for syphilis until the 1960s. The fol-
lowing describes the case of a patient who received mercu-
rial chemotherapy for syphilis forty years ago and
developed misunderstood neurological symptoms.
Case presentation
In September 2004, a 67-year-old Italian man presented
to our medical center. In 1964 he was subjected to heavy
metal (mercurials) therapy to treat a syphilis infection.
The patient remembered that the treatment (which was
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performed one time a week for 4 months) consisted in 10
ml intravenous injection of a mercurial solution (possibly
calomel, e.g. mercurous chloride, Hg2Cl2, or cinnabar, e.g.
mercury sulphide, HgS). Contemporarily, the patient was
administered with penicillin (he referred the daily dose of
500,000 units, at alternative months, for 12 months). The
patient completely recovered from the disease. However,
ten years after (in 1974), he developed some symptoms
such as shiver, pallor, asthenia, which lasted for 2 weeks,
then disappeared. Such symptoms recurred about any two
years. The patient has been examined by a physician, who
found hepatomegaly, whereas the blood tests revealed
increased azotemia. In 1984, the patient developed con-
vulsions (3 episodes), and 8 years ago he presented head-
ache, tremors, vertigo (often resulting in falling out of bed
during the night), memory loss, anxiety, depression,
insomnia, muscular cramps, tachycardia. These and previ-
ous symptoms were never attributed to any one specific
disease by the internists and neurologists who visited the
patient over the course of forty years. Only more recently
(five years ago) the patient was examined by a physician
expert in chelation therapy. The physician, by using the
bioresonance method (VEGA test) evidenced the presence
of elevated levels of mercury in the patient's body. The
physician collected from the patient some samples of
urine and analyzed them for mercury. The samples
revealed levels of mercury <4 μg/g creatinine, which rep-
resent the normal urine reference range of this metal. The
same physician provoked the mercury "challenge" of the
patient, by treating him with disodium edetate (EDTA) (2
g/10 ml, Salf, Brescia, Italy) diluted in 500 ml physiologi-
cal saline and intravenously administered by slow infu-
sion (about 90 min) and inviting him to collect urine for
12 hours. After the challenge, the urine mercury levels
were 10 μg/g creatinine. The patient has remembered at
this time the old mercurial therapy and was addressed by
the physician to our centre to perform the chelation ther-
apy. We took the patient's anamnesis, and his past and
recent blood tests. On the whole these tests revealed nor-
mal levels, with the exception of increased creatinine
serum values (1.3 ± 0.7 mg/dL = mean ± SEM, reported in
ten different blood tests taken between 1990 and 2004)
and a reduced creatinine clearance (63.60 ± 6.2 ml/min).
The inorganic form of mercury, as cinnabar, has been
shown to possess neurotoxicological effects, when orally
administered in mice [3]. In fact, Huang et al. have dem-
onstrated that mercury of cinnabar (10 mg/kg/day,
through oral application by gavage for 11 consecutive
weeks) could be absorbed by gastro-intestinal tract and
significantly accumulated in cerebral cortex, cerebellar
cortex, liver and kidney. Indeed, inorganic mercury is able
to pass the blood-brain barrier. A recent work suggest that
mercury uptake into hair mimics uptake into brain for
both organic and inorganic mercury, e.g. the hair is the
best biological indicator of mercury specie levels [4]. Even
if the patient was treated with mercurials many years ago,
we decided to measure the concentration of heavy metals
in his hair samples, having the patient especially neuro-
logic symptoms [3]. We have also measured, before and
after the chelation therapy, the oxidative stress profile of
the patient, tacking into account that the levels of endog-
enous antioxidant systems could improve, as compensa-
tory pathophysiological response to the oxidative damage
induced by mercury [5]. Indeed, we measured the patient
plasmatic levels of the reduced and oxidized forms of glu-
tathione (GSH and GSSG, respectively), and the levels of
reactive oxygen species (ROS) (expressed in Carratelli
Units or U CARR).
Hair samples were taken from the occipital and temporal
regions of the head. Samples were collected with scissors
from three different areas of the scalp by cutting 1 cm
above hair insertion. About 200 mg of hair samples were
obtained, stored in plastic envelopes and transported to
the Laboratory of Toxicology (Doctor's Data Inc., St
Charles, IL, USA). Hair heavy metal concentrations were
determined by Inductively Coupled Plasma-Mass Spec-
trometry (which guaranteed precision and accuracy of
measurements) and were expressed in micrograms per
gram (μg/g).
The first hair sample was taken on 3 September 2004. It
revealed a high content of bismuth (0.23 μg/g: reference
values ≤ 0.060 μg/g) and mercury (3.2 μg/g; reference val-
ues ≤ 1.1 μg/g) (Figure 1A). The patient was given chela-
tion therapy by intravenous EDTA (2 g in 500 ml saline in
about 90 min). The therapy was administered once a week
for the duration of a year. We also recommended a diet
rich in vitamins and vegetables and invited him to drink
large quantities of water. Six months after the beginning
of the therapy the patient reported that some of the neu-
rological symptoms had disappeared. He did not fall out
of bed at night and had recovered his memory. A year after
EDTA chelation therapy was initiated, on 7 September
2005, we carried out the second evaluation of heavy metal
levels in the hair (Figure 1B). It showed a very significant
increase of mercury levels (11 μg/g) and the normaliza-
tion of bismuth levels (0.021 μg/g). We continued chela-
tion therapy once a week for another year and on 29
September 2006 carried out the third evaluation of heavy
metal levels in the hair (Figure 1C). This evaluation
showed mercury levels of 1.6 μg/g. We then administered
chelation therapy once monthly to the patient until hair
mercury levels were normal. During these periods, the
neurological symptoms of the patient (anxiety, depres-
sion, insomnia) completely disappeared, his muscular
skeletal cramps improved. During the chelation therapy
with EDTA we monitored the creatinine levels of the
patient once every 90 days. These levels improved after theCases Journal 2009, 2:199 http://www.casesjournal.com/content/2/1/199
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Temporal heavy metal levels in the hair of the patient Figure 1
Temporal heavy metal levels in the hair of the patient. A = 3 September 2004; B = 7 September 2005; C = 29 Septem-
ber 2006.
A
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beginning of chelation therapy over the eight successive
evaluations carried out (1.0 ± 0.5 mg/dL), as well as the
creatinine clearance values (70.20 ± 5.4 ml/min). Before
the beginning of the chelation therapy (which started in
September 2004) the patient blood tests showed a GSH/
GSSG ratio of 6 and ROS values of 515 U CARR. At the
end of chelation (in October 2006) the values were: GSH/
GSSG = 13 and ROS = 308 U CARR. At the end of the che-
lation therapy, we have also measured the urine mercury
levels after a 12-h period collection following the EDTA
challenge: they were < 4 μg/g creatinine.
Discussion
The main three forms of mercury exposure today are: 1)
inorganic mercury, which includes elemental metallic
mercury (Hg0) as mercury vapour from amalgam tooth
filling, or its mercuric (Hg++) oxidation state from food, 2)
methyl-mercury (CH3Hg+) from fish or sea mammalians,
3) ethyl-mercury as preservative thimerosal used in vac-
cines. In addition, some people are exposed to mercury in
occupational settings. The three species of mercury are
transported by different mechanisms in the body [6].
We have reported here the case of a patient who was
administered with compounds of mercury for the treat-
ment of syphilis many years ago. The patient suffered neu-
rological symptoms for many years which were never
attributed to previous mercury treatment. He manifested
the neurologic symptoms about 10 years after the therapy
with mercurials. Such mercurials were possibly the forms
of inorganic mercury known as calomel or cinnabar [7].
We have assumed that inorganic mercury intravenously
injected to the patient was then distributed to all tissues
through the bloodstream. Hg2+ from inorganic mercury
can be biotransformed to Hg0 (in kidney, liver or spleen),
then excreted by urine and feces, but Hg0 can be also con-
verted to Hg2+ in brain and kidney [6]. Hg2+ can be bound
by EDTA because its high affinity, as reported in the Figure
2. The presence of mercury in the urine's patient after chal-
lenge with EDTA as well as the presence of mercury in his
hair stimulated us to submit the patient to the chelation
therapy.
The chelating drugs used as antidotes to metal toxicity are
numerous [8]. Among them EDTA, which is able to bind
to many divalent ions with a different affinity, has been
used successfully to treat lead intoxication [9,10]. The
selection of EDTA for the treatment of mercury poisoning
has been justified by the following arguments: i) we neces-
sitated to possibly select a "long-term" chelating treat-
ment, since the mercury poisoning of the patient occurred
many years ago. The chelating agents proposed for treat-
ing human cases of mercury poisoning, e.g. DMPS
(dimercaptopropane-1-sulphonate acid), DMSA (dimer-
captosuccinic acid), DPA (D-penicillamine) or NAPA (N-
acetyl-D-penicillamine), are responsible for many side
effects and are not used for long time; ii) the treatment
with these chelating agents is preferably performed orally
and not intravenously; we found that only the intrave-
nously administered chelating agent was able to reach the
organs and to bind and remove the mercury; iii) we tested
the in vivo chelating activity of EDTA and we showed that,
by using the "challenge" technique, the urine levels of all
toxic metals present in the body's patient were increased
(not shown personal data). Previously is has been shown
that EDTA use improved renal function and slowed down
the progression of renal insufficiency in non-diabetic
patients exposed to environmental lead [11]. EDTA in
vitro performs most stable complexes with both Pb++ and
Hg++ (Figure 2). EDTA treatment is the only chelating
agent successfully in vivo intravenously used over a four-
year period without side effects in non-diabetic chronic
kidney diseases [12].
The first hair sample (Figure 1A) of our patient revealed
an elevated content of mercury. Did such levels reflect the
old contamination of the patient by mercury-containing
drugs? We think that such levels could reflect the dietary
habits of the patient, who in the later 5 years was eating
seafood for three days a week. However, the second hair
sample (Figure 1B) revealed a significant increase of mer-
cury levels one year after chelation therapy. During this
year the patient avoided eating fish and sea mammals, fol-
lowing our suggestions, to avoid further sources of mer-
cury. We hypothesize that long term EDTA intravenous
treatment was able to remove mercury from the tissues
and to favour its elimination through the kidneys and
hair. The third hair sample (Figure 1C), obtained after an
In vitro affinity of EDTA for metal ions Figure 2
In vitro affinity of EDTA for metal ions. The curve rep-
resents the affinity of EDTA for different metals, in relation 
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additional year of treatment with EDTA and characterized
by a significant reduction of mercury levels, showed that
the removal of mercury from the tissues was nearly com-
plete.
This is the first study reporting the beneficial effects of
EDTA chelating therapy to remove an old mercury intoxi-
cation. The intravenously injected inorganic mercury
reaches the brain via blood circulation. The mercury dep-
osition in the brain provokes many irreversible neurolog-
ical features, whose improvement relies on the removal of
mercury. The neurologic symptoms were not due to the
syphilis itself, because the patient, following the treat-
ment with mercurials and penicillin, completely recov-
ered from the disease and did not develop the third stage
of the disease, which is the neurosyphilis. Indeed, the neu-
rologic symptoms of the patient were attributable to the
mercurial treatment. Such symptoms were different from
those due to known neurologic disorders. We have shown
here that long term treatment with EDTA was able to cure
neurological symptoms in a patient who was adminis-
tered inorganic mercury to treat a chronic bacterial infec-
tion. During such therapy the patient was day by day
improved in the symptoms. Chelation therapy with EDTA
did not induce any side effects in the main site of EDTA
elimination at the time, e.g. the kidneys, as shown by the
improved creatinine levels during chelation treatment.
Our previous study also demonstrated that the functions
of rats kidneys affected by ischemic injury were improved
by EDTA treatment [13]. The patient's neurologic symp-
tom disappeared following the end of the therapy until
today. The improvement of ROS and glutathione blood
levels by the chelation therapy and the absence of mercury
levels in urine following the last EDTA treatment confirm
our suggestions.
Conclusion
The reported clinical case should encourage the use of
EDTA chelation therapy in patients who suffer from mer-
cury intoxication.
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